Merck & Co. revenue 2006-2024
Published by
The revenue of Merck & Co. increased significantly in 2024, rising from 60 billion U.S. dollars in 2023 to 64 billion U.S. dollars in 2024. During 2021, Merck spun-off its women’s health, biosimilars and established brands businesses into a new publicly traded company named Organon & Co.
Revenues lifted by sales of cancer treatments
The majority of Merck’s revenue comes from its pharmaceutical segment, which includes human health and vaccine products. The company’s oncology franchise, which is dedicated to the study of cancer, generates the largest share of its pharmaceutical revenues. Revenues of Keytruda, a drug used to fight cancer, were particularly strong over the last years – increasing by around five billion U.S. dollars between 2023 and 2024.
The importance of investing in innovation
Higher sales of Keytruda contributed to the increase in Merck’s revenue in 2024. Developing commercially successful products, such as Keytruda and Gardasil, is essential if Merck & Co. wants to compete in the industry. The company continues to recognize the importance of research and development and has annually invested many billions of U.S. dollars in the search for innovative medicines over the last few years, and a record high of 30.5 billion dollars of R&D spending in 2023.
